Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
  • Publication Type:
    Journal article
  • Publication Sub Type:
  • Authors:
    Leandro MJ, Edwards JC, Cambridge G
  • Publication date:
  • Pagination:
    883, 888
  • Journal:
    Annals of the Rheumatic Diseases
  • Volume:
  • Issue:
  • Print ISSN:
  • Keywords:
    1200, activity, adult, ADVERSE, adverse events, Aged, Aged, 80 and over, AGENT, AGENTS, American, antibodies, Antibodies, Monoclonal, Antibody, Antirheumatic Agents, Arthritis, Arthritis, Rheumatoid, As, B CELL, B Lymphocyte, B-cell, B-lymphocyte, B-Lymphocytes, cell, chosen, clinical, Clinical trial, CLINICAL-TRIAL, COHORT, COMBINATION, Combined Modality Therapy, CONTROLLED TRIAL, CP, CRITERIA, Cyclophosphamide, DEPLETION, design, disease, dose, Dose Response, DOSE-RESPONSE, Drug Administration Schedule, drug effects, drug therapy, Drug Therapy, Combination, DURATION, EFFICACY, EVENTS, Female, FOLLOW, Follow-Up Studies, GRADE, IM, IMPROVEMENT, IV, LA, LYMPHOCYTE, Lymphocyte Depletion, Male, Methods, Middle Age, Observation, Open, Other, outcome, Patient, patients, phase, PHASE II, PHASE-II, PR, Prednisolone, PROGRESS, Protocol, response, Result, Rheumatoid arthritis, RHEUMATOID-ARTHRITIS, Rheumatology, rituximab, SAFE, Safety, SCORES, Severity of Illness Index, therapeutic use, therapy, treatment, Treatment Outcome, Treatments, TRIAL, TRIALS
  • Notes:
    UI - 22215432 DA - 20020913 IS - 0003-4967 LA - eng PT - Clinical Trial PT - Journal Article RN - 0 (Antibodies, Monoclonal) RN - 0 (Antirheumatic Agents) RN - 0 (rituximab) RN - 50-18-0 (Cyclophosphamide) RN - 50-24-8 (Prednisolone) SB - IM
OBJECTIVES: To obtain evidence for dose response and to extend evidence of safety and efficacy for B lymphocyte depletion in rheumatoid arthritis. METHODS: Twenty two patients with rheumatoid arthritis received a total of 29 treatments with five different combinations of rituximab (RTX), cyclophosphamide (CP), and/or high dose prednisolone (PR) on an open basis as follows; cohort I: RTX 1400 mg/m(2), CP 750x2+PR; cohort II: RTX 300-700 mg/m(2), -CP+/-PR); cohort III: RTX 600-700 mg/m(2), CP 750x2+PR; cohort IV: RTX 1200 mg/m(2), CP 750x2-PR; cohort V: RTX 500 mg/m(2), CP 750x2+PR. American College of Rheumatology (ACR) criteria of improvement at six months were chosen as the primary outcome measure. Disease activity scores and total duration of improvement and of B cytopenia were also recorded. RESULTS: No major adverse events attributable to treatment were seen. ACR grades of improvement at six months were as follows: cohort I: ACR70x3, ACR50x2; cohort II: ACR20x1, ACR0x3; cohort III: ACR70x6, ACR50x2, ACR20x2; cohort IV: ACR70x2, ACR50x2, ACR20x1, ACR0x1; cohort V: ACR0x4. CONCLUSIONS: B lymphocyte depletion in rheumatoid arthritis has so far proved to be safe and associated with major improvement with protocols including RTX 600 mg/m(2) or more and CP, but not with more limited protocols. These observations provide an initial basis for the design of formal trials of B cell depletion and other B cell directed treatments, including a phase II controlled trial now in progress
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by